Turgut Celen Yelda, Peker Yüksel
Sleep Medicine Unit, Department of Neurology and Rehabilitation Medicine, Skaraborg Hospital, Skövde, Sweden.
Anadolu Kardiyol Derg. 2010 Jun;10(3):274-80. doi: 10.5152/akd.2010.070.
Obstructive sleep apnea (OSA) is a common condition in patients with cardiovascular diseases (CVD). The first line treatment of OSA is continuous positive airway pressure (CPAP), which reduces daytime sleepiness and improves quality of life in sleep-clinic based populations. However, in the cardiac populations, the majority of OSA subjects do not report daytime sleepiness. To date, there is not enough evidence to draw the conclusion that all CVD patients should be investigated for OSA and subsequently be treated with CPAP. The current article focuses on the available research evidence addressing the impact of CPAP on the cardiovascular consequences of OSA in both clinic- and population-based cohorts.
阻塞性睡眠呼吸暂停（OSA）是心血管疾病（CVD）患者中的常见病症。OSA的一线治疗方法是持续气道正压通气（CPAP），这可减少日间嗜睡并改善基于睡眠诊所人群的生活质量。然而，在心脏疾病人群中，大多数OSA患者并未报告有日间嗜睡症状。迄今为止，尚无足够证据得出所有CVD患者均应接受OSA筛查并随后接受CPAP治疗这一结论。本文重点关注现有研究证据，这些证据涉及CPAP对基于诊所和人群的队列中OSA心血管后果的影响。
